IGC Pharma Inc. (IGC) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 6 wire items for IGC, including 3 market updates and 3 SEC filings. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, TTM
- $1.26M
- Revenue growth
- +13.9%
- Net income, TTM
- -$8.11M
- Net margin
- -643.7%
- Cash
- $377.0K
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks24+25%
2026-05-172026-11-08
Mix1090d
- Market5(50%)
- SEC Filings3(30%)
- Insider2(20%)
Activity · 52 weeks6756 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- NEWSIGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateCALMA randomized 170 participants; topline results expected following last patient- last dose, database lock and unblinding POTOMAC, MD / ACCESS Newswire / November 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies and AI-enabled tools for Alzheimer's disease, today reported financial results and business updates for the third quarter ended September 30, 2026."CALMA enrolled is complete." said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Once the last participant receives the last dose, we will verify the data using AI, lock the database from further changes, unblind the study, and
- SECSEC Form 10-Q filed by IGC Pharma Inc.10-Q - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout NearsCanada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease. Agitation is one of the hardest symptoms for families to manage. POTOMAC, MD / ACCESS Newswire / November 5, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, "Method and Composition for Treating CNS Disorders". The patent covers the composition of IGC-AD1, an investigational oral therapy for agitation in Alzheimer's.With this
- SECSEC Form DEFA14A filed by IGC Pharma Inc.DEFA14A - IGC Pharma, Inc. (0001326205) (Filer)
- SECSEC Form DEF 14A filed by IGC Pharma Inc.DEF 14A - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial DeploymentPOTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM, a new application layer designed to bring its patent-pending MINT-AD Alzheimer's AI platform closer to real-world healthcare applications, including early Alzheimer's risk stratification, cognitive health tracking, clinical trial optimization, and personalized brain-health programs. The introduction represents an important expansion of IGC Pharma's Artificial Intelligence and Alzheimer's disease stra
- INSIDERCEO Mukunda Ram gifted 200,000 shares, decreasing direct ownership by 3% to 6,675,563 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERPFO Grimaldi Claudia gifted 150,000 shares, decreasing direct ownership by 4% to 3,271,092 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- NEWSIGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia. Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen the evaluable dataset for end-of-treatment, secondary, and exploratory analyses. Following the protocol-defined six-week treatment period, final participant dosing is expected to complete in early November,
- NEWSIGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosurePhase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA trial of IGC-AD1 reached the Company's previously disclosed 146-patient baseline randomization target. Subsequent to quarter-end, CALMA has continued its final planned over-enrollment phase and is now within
- NEWSIGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutPOTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026. CALMA has randomized 160 participants to date. IGC Pharma expects to close enrollment after up to additional participants, marking a key final enrollment milestone before patient follow-up,
- NEWSIGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short CampaignPOTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California. According to the United States Attorney's Office for the Central District of California, Andrew Left, founder of Citron Research, was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud. The verdict follows a federal indictment that i
- SECIGC Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative WorkflowSeven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will showcase its artificial intelligence portfolio across seven scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London. IGC Pharma is building computational infrastructure designed to accelerate data integration, pa
- NEWSIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the CompanySenior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Chief Executive Officer Ram Mukunda and Principal Financial Officer Claudia Grimaldi have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share. The shares were purchased through the cancellation of approximately $1.15 million of outstanding amounts owed by
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- INSIDERCEO Mukunda Ram was granted 2,226,475 shares, increasing direct ownership by 48% to 6,875,563 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- INSIDERPFO Grimaldi Claudia was granted 2,048,378 shares, increasing direct ownership by 149% to 3,421,092 units (SEC Form 4)4 - IGC Pharma, Inc. (0001326205) (Issuer)
- NEWSIGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative WorkflowPatent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS Newswire / June 23, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled healthcare technologies, today announced the beta version of its proprietary Agentic Harmonization Assistant ("AHA"), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. The announcement comes as IGC advances IGC-AD1, it
- NEWSIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline AnalysisCompany Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline. The Company's prior enrollment updates described progress toward this 146-patient target. Based on observed and potential attrition between baseline, Week 2, and end-of-treatment assess
- NEWSAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 CatalystsPOTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.IGC Pharma's lead program, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease
- SECIGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - IGC Pharma, Inc. (0001326205) (Filer)
- NEWSIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline AnalysisApproximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with approximately 80% of targeted participants having completed trial participati
- NEWSIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's disease ("AD"), today announced the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC") for the quarter ended March 31, 2026. "During the first quarter, we continued to execute against our core priorities by advancing CALMA, expanding our clinical site network, and strengthening the AI and intellectual property components of our Alzheimer's strategy with disciplined capi
- SECSEC Form 10-Q filed by IGC Pharma Inc.10-Q - IGC Pharma, Inc. (0001326205) (Filer)
IGC FAQ
9 questionsWhat does IGC Pharma Inc. do?
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; hemp-based CBD...What is the latest news on IGC?
In the last 30 days Quantisnow tracked 6 wire items for IGC: 3 market updates and 3 SEC filings. The most recent was published on November 9, 2026.What is IGC revenue?
IGC Pharma Inc. (IGC) reported $1.26M of revenue for the twelve months ended Sep 30, 2026. That is up 13.9% from the year before. Revenue for fiscal 2025 was $1.27M.Is IGC profitable?
No. IGC Pharma Inc. reported a net loss of $8.11M for the twelve months ended Sep 30, 2026.How much cash and debt does IGC have?
IGC Pharma Inc. reported $377.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does IGC stock trade?
IGC Pharma Inc. (IGC) is listed on AMEX.What sector and industry is IGC in?
IGC Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IGC?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare IGC side-by-side with any of them on Quantisnow.How can I track IGC on Quantisnow?
Quantisnow aggregates IGC Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IGC to receive live email and push alerts on every new disclosure.